This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Does Teladoc's Acquisition Strategy Boost Growth and Global Footprint?
by Tanuka De
TDOC's steady stream of acquisitions is expanding its global reach and lifting growth across key segments in 2025.
HCAPositive Net Change TDOCPositive Net Change ELVPositive Net Change
medical
Hims & Hers Accelerates Its Clinician-Led, Platform-Driven Care Model
by Debanjana Dey
HIMS expands its connected care model with new diagnostics, hormonal health services and at-home testosterone treatments.
GDRXPositive Net Change HIMSPositive Net Change DOCSPositive Net Change
medical medical-devices
Veeva Systems Stock Down Despite Q3 Earnings & Revenues Top Estimates
by Zacks Equity Research
VEEV posts a Q3 earnings beat with stronger subscription growth and higher full-year guidance, highlighting continued momentum.
BSXPositive Net Change ISRGPositive Net Change VEEVNegative Net Change MEDPPositive Net Change
earnings medical medical-devices
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
by Zacks Equity Research
ANGO benefits from NanoKnife, clinical milestones and a balanced portfolio despite tariff headwinds.
BSXPositive Net Change ANGOPositive Net Change ISRGPositive Net Change MEDPPositive Net Change
medical medical-devices
Can Linzess Continue to Aid IRWD's Top Line After a Strong Q3?
by Kanishka Das
Ironwood gains momentum as rising U.S. demand for Linzess drives strong profit growth during the third quarter.
AZNPositive Net Change IRWDNegative Net Change ABBVPositive Net Change
medical
AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo
by Zacks Equity Research
AstraZeneca secures FDA approval to expand Koselugo's use to treat adult NF1 patients with inoperable PN.
AZNPositive Net Change MRKPositive Net Change ADMAPositive Net Change EDITNegative Net Change
biotechnology biotechs medical pharmaceuticals
NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth
by Zacks Equity Research
Novartis boosts long-term sales forecasts as blockbuster drugs like Kisqali and Scemblix drive strong momentum across its portfolio.
NVSPositive Net Change BAYRYPositive Net Change FOLDPositive Net Change RNANegative Net Change
biotechnology biotechs medical pharmaceuticals
Here's How ANIP's Rare Disease Portfolio Is Driving Top-line Growth
by Sundeep Ganoria
ANI Pharmaceuticals' rare disease surge, led by Cortrophin Gel, drives major 2025 revenue gains despite softer ophthalmology sales.
REGNPositive Net Change ABBVPositive Net Change ANIPPositive Net Change
biotechs medical pharmaceuticals
LH Shares Gain Following Publication of New Plasma Detect MRD Data
by Zacks Equity Research
Labcorp shares edge higher as new studies spotlight Plasma Detect's role in tracking MRD and improving post-surgery cancer detection.
BSXPositive Net Change LHPositive Net Change ISRGPositive Net Change MEDPPositive Net Change
medical
TLRY vs. CRLBF: Which Cannabis Player Offers Greater Upside?
by Sridatri Sarkar
Tilray Brands' global expansion and strong Canadian momentum spotlight its edge as investors weigh upside against Cresco Labs' slower growth.
TLRYPositive Net Change CRLBFPositive Net Change
marijuana medical
Why 2025 is a Dynamic and Transformative Year for Collegium
by Abhinab Dasgupta
COLL's bold buybacks, board refresh and expanding ADHD push highlight a year of strategic moves and rising momentum.
ANIPPositive Net Change COLLPositive Net Change AMRXPositive Net Change
medical
Hologic's GYN Surgical Delivers a Standout Quarter: What's Behind It?
by Moumi Mondal
HOLX's GYN Surgical segment posts its strongest fiscal 2025 growth as MyoSure, Fluent and Gynesonics fuel a standout quarter.
JNJPositive Net Change BDXPositive Net Change HOLXPositive Net Change
medical medical-devices
New Strong Sell Stocks for Nov. 21st
by Zacks Equity Research
ALVO, AKZOY and ALG have been added to the Zacks Rank #5 (Strong Sell) List on November 21, 2025.
ALGPositive Net Change AKZOYPositive Net Change ALVOPositive Net Change
industrial-products medical
2025's Top 3 Breakout Stocks for Active Traders: Don't Miss Out!
by Tirthankar Chakraborty
ORLA, FIGS and CMPX emerge as breakout candidates as traders scan for stocks nearing or clearing key resistance levels.
ORLANegative Net Change FIGSPositive Net Change CMPXPositive Net Change
biotechnology medical retail
Four PEG-Driven GARP Winners for the Uncertainty of November 2025
by Urmimala Biswas
Four PEG-driven GARP picks emerge as compelling options amid market turmoil, with ALL, SANM, PAHC and ENS highlighted for their strong growth metrics.
ALLPositive Net Change SANMPositive Net Change ENSPositive Net Change PAHCPositive Net Change
finance industrial-products insurance medical medical-devices tech-stocks
Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?
by Ekta Bagri
BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.
BMYPositive Net Change JNJPositive Net Change PFEPositive Net Change CYTKPositive Net Change
biotechnology biotechs medical pharmaceuticals
AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results
by Zacks Equity Research
Agios slides to a 52-week low after mixed phase III RISE UP data show a hemoglobin boost but no significant cut in pain crises.
ALKSPositive Net Change AGIOPositive Net Change CRMDNegative Net Change FULCPositive Net Change
biotechs medical
TDOC vs. LFMD: Which Telehealth Stock Is Better for Your Portfolio?
by Tanuka De
TDOC and LFMD face contrasting paths as telehealth demand climbs, with fundamentals and growth plans shaping which stock stands out.
TDOCPositive Net Change LFMDPositive Net Change
medical
COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know
by Zacks Equity Research
Cogent Biosciences soars as its bezuclastinib combo delivers strong phase III GIST results, driving momentum toward key regulatory filings.
ADMAPositive Net Change EDITNegative Net Change COGTPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug
by Zacks Equity Research
Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.
PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
4 Stocks Trading Near 52-Week High With More Upside Potential
by Vasundhara Sawalka
Stocks like PAHC, ATRO, COMM and HRTG are seeing price strength and have a high chance of carrying the momentum forward.
ATROPositive Net Change COMMPositive Net Change PAHCPositive Net Change HRTGPositive Net Change
aerospace artificial-intelligence finance medical tech-stocks
Best Momentum Stock to Buy for Nov. 20th
by Zacks Equity Research
PAHC, SHIP and BCAL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 20, 2025.
PAHCPositive Net Change SHIPPositive Net Change BCALPositive Net Change
finance medical transportation
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
by Zacks Equity Research
Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.
MRKPositive Net Change GILDPositive Net Change ADMAPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
CVS Aetna's New Generative AI Assistant Aims to Simplify Health Care
by Moumi Mondal
CVS Health's Aetna debuts an embedded generative AI assistant designed to simplify benefits navigation and elevate the consumer health experience.
CAHPositive Net Change CVSPositive Net Change CNCPositive Net Change
medical medical-devices
RVP Stock Rises Post Q3 Earnings Despite Tariff and Cost Pressures
by Zacks Equity Research
Retractable Technologies reports improved third-quarter 2025 earnings driven by better margins, investment gains and a shift toward domestic production.
RVPNegative Net Change
earnings medical medical-devices